I do know the dosage and some details but I'm not sure I should mention them here. Suffice to say that a miracle was achieved.
At IPO it was hard for Noxopharm, absent of new clinical and new mechanism of action data, to clearly differentiate its first generation claims from the original Novogen claims ... not impossible, just difficult.That clinical and MoA data has been maturing and about 12 months ago Noxopharm embarked on its 2nd generation of patent applications. I believe the 2nd generation usage claims surpass that of the 1st generation ... though I can't as yet personally confirm that.
I'd also like to thank RBx for his in-depth NOX posting history ... I think I've read every one.
NOX Price at posting:
95.0¢ Sentiment: Hold Disclosure: Held
